ART Expands Engineering and Operational Strengths of Executive Team by Appointing Mario Khayat as Vice President Optical Products.MONTREAL -- ART Advanced Research Technologies Inc. ("ART") (TSX TSX Toronto Stock Exchange (TSE before April, 2002) TSX Transfer from Stack Pointer to Index TSX True Space Extension :ARA Ara or Arrah (both: ŭ`rə), city (1991 pop. 157,082), Bihar state, NE India, on the Son Canal. A major road and rail junction, it is the administrative center for a district that produces grain, sugarcane, and oilseed. ), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, is pleased to announce the appointment of Mr. Mario Khayat as Vice President, Optical Products (subject to regulatory approval). In this new capacity, Mr. Khayat will report directly to ART's President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Ms. Micheline Bouchard, and have responsibility for all operational matters regarding the SoftScan and eXplore Optix business units. ART's Chief Operating Officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. , Mr. Warren Baker, has been assigned exclusively to lead ART's strategic growth initiatives which will become a key priority for the Company over the next few months as ART is committed to a long-term growth strategy and is currently assessing a number of strategic initiatives and growth opportunities. About Mario Khayat Mr. Khayat joined ART in 2004 as Executive Director, Clinical Systems, with responsibility for the SoftScan development program. He has fifteen years of experience in software and hardware research & development environments in addition to having technical and financial management expertise gained in the telecommunications and medical sectors. Prior to joining ART, Mr. Khayat was Director, Product Management at Evolved Digital Systems (formerly Electromed), a developer and manufacturer of image networking and archiving solutions for the medical sector, from 2003 to 2004, where he helped restructure the product lines and the positioning of the company. He was Manager of the North American North American named after North America. North American blastomycosis see North American blastomycosis. North American cattle tick see boophilusannulatus. network management product line and architecture group at Marconi Optical Networks from 2000 to 2002, where he developed products for the management of hybrid optical networks. From 1996 to 2000, he co-established ACE(i)COMMs' Montreal facilities, where he held successively the positions of Program Manager and Director, R&D Programs. Mr. Khayat also has over ten years of experience in biomedical engineering Biomedical engineering An interdisciplinary field in which the principles, laws, and techniques of engineering, physics, chemistry, and other physical sciences are applied to facilitate progress in medicine, biology, and other life sciences. and in heading technical services in the hospital sector in the Montreal metropolitan area. Mr. Khayat began his career at CAE (1) (Computer-Aided Engineering) Software that analyzes designs which have been created in the computer or that have been created elsewhere and entered into the computer. Electronics as an Electronics Engineer in the Electronic Warfare Department. Mr. Khayat holds a Bachelor of Science in Biomedical Engineering A Bachelor of Science in Biomedical Engineering is a kind of bachelor's degree typically conferred after a four year undergraduate course of study in biomedical engineering (BME). from Boston University, a Masters in Electrical Engineering as well as a Masters in Business Administration from McGill University. About ART ART Advanced Research Technologies Inc. is a leader in optical molecular imaging products for the healthcare and pharmaceutical industries. ART has developed two products based on its innovative technology. The first is eXplore Optix(TM), a molecular imaging device designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs. eXplore Optix(TM) is distributed by GE Healthcare and is used by industry and academic leaders worldwide to bring new and better treatments to patients faster. The second is SoftScan(R), a medical imaging device designed to improve the diagnosis and treatment of breast cancer. ART is commercializing its products in a global strategic alliance with GE Healthcare, a world leader in mammography mammography, diagnostic procedure that uses low-dose X rays to detect abnormalities in the breasts. The early diagnosis of breast cancer made possible by the routine use of mammography for screening women increases a woman's treatment alternatives and improves her and imaging. ART's shares are listed on the TSX under the ticker symbol Ticker Symbol An arrangement of characters (usually letters) representing a particular security listed on an exchange or otherwise traded publicly. When a company issues securities to the public marketplace, it selects an available ticker symbol for its securities which investors ARA. Visit ART online at www.art.ca This press release may contain forward-looking statements subject to risks and uncertainties that would cause actual events to differ materially from expectations. These risks and uncertainties are described in ART Advanced Research Technologies Inc.'s regulatory filings with Canadian Securities Commissions and the Securities and Exchange Commission in the United States. ART Advanced Research Technologies Inc. (TSX:ARA) |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion